Initial Therapeutics

Initial Therapeutics is develops small-molecule medicines to prevent pathogenic protein synthesis. Their approach is different from protein degradation and other interventions that recognize and address proteins only after they are fully formed. Initial Therapeutics develops therapeutics for cancer and neurological disorders using proprietary technology to address high-confidence drug targets.

Jobs: